Results 21 to 30 of about 88,672,115 (295)
PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity
OncoImmunology, 2021 Anti-programmed cell death-1 (PD-1)/PD-ligand-1 (PD-L1) treatments are effective in a fraction of patients with advanced malignancies. However, the majority of patients do not respond to it.
Haiping Jiang +15 more
doaj +1 more source
LAG-3 in Cancer Immunotherapy [PDF]
, 2010 LAG-3 (CD223) is a cell surface molecule expressed on activated T cells (Huard et al. Immunogenetics 39:213-217, 1994), NK cells (Triebel et al. J Exp Med 171:1393-1405, 1990), B cells (Kisielow et al. Eur J Immunol 35:2081-2088, 2005), and plasmacytoid dendritic cells (Workman et al.
Monica V, Goldberg, Charles G, Drake
openaire +2 more sources
Lymphocyte activation gene-3 : the expression and function in the immune system [PDF]
, 2006 Lymphocyte activation gene-3 (LAG-3) is the structural homologue of a well-known TCR co-receptor CD4. Recently, it has been suggested that LAG-3 might play a role in modulation of immune response, by being a negative regulator of T cell activation. To
Kisielow, Malgorzata
core +1 more source
OncoImmunology, 2020 Despite the success of immunotherapy using checkpoint blockade, many patients with solid tumors remain refractory to these treatments. In human cancer, the experimental options to investigate the specific effects of antibodies blocking inhibitory ...
Nicolas Gestermann +8 more
doaj +1 more source
Genomic and immunologic correlates of LAG-3 expression in cancer
OncoImmunology, 2020 Immune checkpoint blockade leads to unprecedented responses in many cancers. Although currently available agents mostly target the PD-1 and CTLA-4 pathways, agents targeting the immune checkpoint protein LAG-3 are under active clinical development, and ...
Anshuman Panda +4 more
doaj +1 more source
Targeting LAG-3, TIM-3, and TIGIT for cancer immunotherapy
Journal of Hematology & Oncology, 2023 In one decade, immunotherapy based on immune checkpoint blockades (ICBs) has become a new pillar of cancer treatment following surgery, radiation, chemotherapy, and targeted therapies.
Letong Cai +4 more
doaj +1 more source
Exploring new frontiers in LAG-3 biology and therapeutics. [PDF]
Trends Pharmacol SciLymphocyte activation gene-3 (LAG-3) has emerged as a critical immune checkpoint receptor primarily modulating T-cell responses through distinct immune regulatory mechanisms. Recent advances have elucidated LAG-3's complex receptor-ligand interactions, structure-function relationships, and unique signaling pathways.
Wang J +4 more
europepmc +3 more sources
LAG-1 spatial accumulation and germline autonomous function to promote the stem cell fate.
, 2020 (A) Diagrams of tagged endogenous lag-1 alleles, lag-1(oz530[lag-1::3xHA]) (top) and lag-1(oz536oz537[lag-1::degron::3xHA]) (bottom). Purple boxes, exons; lines, introns; pink boxes, untranslated region; yellow boxes, 3xHA; green box, degron.
Ariz Mohammad (5411930) +6 more
core +1 more source
Frontiers in Oncology, 2023 IntroductionImmune checkpoint inhibitor (ICI) is one of the standard treatment strategies in triple negative breast cancer (TNBC). However, the benefit of ICI with chemotherapy is limited in metastatic TNBC.
Ji-Yeon Kim +12 more
doaj +1 more source
Lag-time probability distributions: Theory and simulations.
, 2021 (A-B) Lag-time distribution after 10 cycles as obtained in the simulation of the individual-based model in both the additive (A) and the multiplicative (B) case, for different antibiotic-exposure periods, Ta = 3, 5 and 8h (marked with different colours).
Miguel A. Muñoz (8598015) +2 more
core +1 more source